Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis
Journal of the Peripheral Nervous System · 2024
DOI: 10.1111/jns.12624 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, 2024. Verfasst von Karla Cárdenas-Soto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Benzoxazoles, Skin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Pfizer Global Medical Grants.
Abstract (Originalsprache)
Background
ATTR (ATTRv) amyloidosis neuropathy is characterized by progressive sensorimotor and autonomic nerve degeneration secondary to amyloid deposition caused by a misfolded transthyretin protein (TTR). Small nerve fiber neuropathy is an early clinical manifestation of this disease resulting from the dysfunction of the Aδ and C small nerve fibers. Tafamidis, a selective TTR stabilizer, has proven its efficacy in the earlier stages of hATTR.
Objectives
To evaluate the clinical course and utility of cutaneous pathological biomarkers in patients with ATTR amyloidosis treated with tafamidis compared to control patients.
Methods
Forty patients diagnosed with early stages of ATTRv amyloidosis (polyneuropathy disability [PND] scores 0‐II) underwent small and large nerve fiber neurological evaluations, and annual skin biopsies for intraepidermal nerve fiber density (IENFD) and amyloid deposition index (ADI) estimation. Thirty patients were allocated to receive tafamidis, and 10 patients served as controls. Tafamidis pharmacokinetics analysis was performed in patients who received the treatment.
Results
At baseline, 12% of patients in stage PND 0 and 28% in PND I displayed small nerve fiber denervation in the distal thigh, whereas 23% and 38%, respectively, in the distal leg. Similarly, 72% and 84% had amyloid deposition in the distal thigh and 56% and 69% in the distal leg. Following 1 year of treatment, the tafamidis group showed significant clinical improvement compared to the control group, revealed by the following mean differences (1) −9.3 versus −4 points ( p =
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- Department of Chemistry, University of Washington, Seattle, Washington, USA.
- Neurophysiology Department, Hospital Shriners, Mexico City, Mexico.
- Centro Neurológico, Centro Médico ABC, Mexico City, Mexico.
- Hospital Medica Sur, Mexico City, Mexico.
- Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Christopher Gibbons, Alejandra González-Duarte
Förderung
- Pfizer Global Medical Grants
Zitieren
APA
Cárdenas-Soto, K., Dominguez, X. H., Cortes, G., Tsai, F., Saniger, M. D. M., Guraieb-Chahin, P., Torres-Ocatvo, B., Gibbons, C., Kelly, J. W., Freeman, R., & González-Duarte, A. (2024). Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.12624
Vancouver
Cárdenas-Soto K, Dominguez XH, Cortes G, Tsai F, Saniger MDM, Guraieb-Chahin P, et al. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis. Journal of the Peripheral Nervous System. 2024. doi:10.1111/jns.12624
BibTeX
@article{CrdenasSoto2024,
author = {Cárdenas-Soto, Karla and Dominguez, Xel-Ha and Cortes, Giovanni and Tsai, Felix and Saniger, Maria Del Mar and Guraieb-Chahin, Paola and Torres-Ocatvo, Benjamín and Gibbons, Christopher and Kelly, Jeffery W and Freeman, Roy and González-Duarte, Alejandra},
title = {Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis},
journal = {Journal of the Peripheral Nervous System},
year = {2024},
doi = {10.1111/jns.12624}
}
EUVIMED